×
About 688 results

ALLMedicine™ Hypereosinophilic Syndrome Center

Research & Reviews  249 results

Mepolizumab in Episodic Angioedema With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT04128371

May 13th, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Treatment of a 4-year-old boy with mepolizumab for Lymphocytic Hypereosinophilic Syndrome.
https://doi.org/10.1016/j.anai.2022.04.031
Annals of Allergy, Asthma & Immunology : Official Publica... Cascio JA, Walsh M et. al.

May 11th, 2022 - Treatment of a 4-year-old boy with mepolizumab for Lymphocytic Hypereosinophilic Syndrome.|2022|Cascio JA,Walsh M,Hoenig K,Davis B,|

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
https://clinicaltrials.gov/ct2/show/NCT05334368

Apr 19th, 2022 - This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis ...

Idiopathic Hypereosinophilic Syndrome Associated With Pulmonary Hypertension in an Infant.
https://doi.org/10.1097/MPH.0000000000002444
Journal of Pediatric Hematology/oncology; Akcabelen YM, Kaya Dinçel G et. al.

Apr 7th, 2022 - Hypereosinophilic syndrome (HES) is a very rare disease during childhood. It involves the different organs like skin, gastrointestinal system, heart and lungs, besides pulmonary hypertension (PHT) is a very rare morbidity of HES that may cause lif...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  10 results

Mepolizumab in Episodic Angioedema With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT04128371

May 13th, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
https://clinicaltrials.gov/ct2/show/NCT05334368

Apr 19th, 2022 - This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis ...

MAP to Provide Access to Nilotinib, for Patients With HES
https://clinicaltrials.gov/ct2/show/NCT04498871

Sep 20th, 2021 - The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health a...

This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme fo...
https://clinicaltrials.gov/ct2/show/NCT00244686

Nov 25th, 2020 - 104317: The market authorisation application for mepolizumab for the indication of hypereosinophilic syndrome (HES) was filed in 2008, but later the file was withdrawn due to outstanding questions from regulator's raised from the application. On t...

see more →

News  5 results

Next Generation of PDGFR Inhibitors Makes Headway in GIST
https://www.onclive.com/view/next-generation-of-pdgfr-inhibitors-makes-headway-in-gist

May 25th, 2021 - Dysregulated platelet-derived growth factor receptor (PDGFR) signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.1,2 Despite the success of these drugs in a range of malignancies...

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs
https://www.onclive.com/view/dr-mesa-on-upcoming-updates-to-nccn-guideline-for-mpns

Dec 20th, 2020 - Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs). The NCCN Guidelines for Myeloproliferative Neoplasms (version 1.2017), which include t...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

Eosinophilic Esophagitis: New Guidelines
https://www.medscape.com/viewarticle/806908_2

Jul 8th, 2013 - Making the Diagnosis The diagnosis of EoE is not uncommon. We didn't see EoE 2 decades ago, but the condition is now being increasingly recognized. Slide 3. (Enlarge Slide) The presentation varies according to age. In adults, 34%-50% of patients p...

see more →

Patient Education  2 results see all →